OVERVIEW

Extending Efficacy: New Approaches for Endocrine-Resistant HR+ HER2- Advanced Breast Cancer is organized by Phillips Group Oncology Communications, inc.

Release Date: February 01, 2026
Expiration Date: February 01, 2027

Learning Objectives:

  1. Describe how different therapeutic classes impact the diverse molecular signaling pathways implicated in breast cancer endocrine resistance.
  2. Evaluate the latest clinical data supporting biomarker-directed therapies to overcome endocrine resistance in MBC.
  3. Discuss emerging clinical data and novel therapeutic strategies for the treatment of patients with endocrine-resistant, HR-positive, HER2-negative metastatic breast cancer without driver mutations.
Credits

Educational Review Systems s accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.0 contact hours (0.10 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days. 

  • 1 Contact Hours
  • 0.1 CEU
  • TARGET AUDIENCE

    PhysicianPharmacistSurgical Oncologists

    SPECIALITIES

    Surgical Oncology

    RELATED ONLINE COURSES